What is the appropriate dosing regimen for mirtazapine, including starting dose, titration schedule, and special considerations for elderly patients or those with hepatic impairment?

Mirtazapine Dosing

Start mirtazapine at 15 mg once daily in the evening, increase to 30 mg after 1-2 weeks if needed, with a maximum dose of 45 mg daily. 1

Standard Dosing Regimen

The FDA-approved dosing is straightforward:

• Starting dose: 15 mg once daily, preferably in the evening before sleep
• Titration: Increase up to 45 mg daily if inadequate response
• Titration interval: Wait at least 1-2 weeks between dose changes to allow adequate time to evaluate response 1
• Steady state: Achieved within 5 days, with approximately 50% drug accumulation 1

Evidence supports that increasing from 15 mg to 30 mg improves outcomes in early non-responders, but further increases beyond 30 mg may not provide additional benefit. A 2015 study demonstrated that patients without initial improvement who increased from 15 mg to 30 mg showed significantly greater symptom reduction compared to those who remained at 15 mg (P = 0.003), but no significant benefit was found when increasing from 30 mg to 45 mg 2.

Special Population Considerations

Elderly Patients

Elderly patients require careful monitoring but not necessarily automatic dose reduction at initiation. 3 However, critical pharmacokinetic differences exist:

• Oral clearance is reduced by 40% in elderly males and 10% in elderly females compared to younger adults 1
• Elimination half-life ranges from 20-40 hours, with females showing longer half-lives (37 hours) versus males (26 hours) 1
• Mirtazapine is listed as a preferred agent for elderly patients with depression alongside citalopram, escitalopram, and sertraline 3

Practical approach for elderly: Start at 15 mg and titrate more cautiously, extending the interval between dose increases to 2-3 weeks rather than 1-2 weeks, given the reduced clearance.

Hepatic Impairment

Patients with hepatic impairment require dose reduction from the outset. 1

• Oral clearance is decreased by approximately 30% in hepatic impairment 1
• Start at 7.5-15 mg daily and titrate slowly with close monitoring
• Mirtazapine undergoes extensive hepatic metabolism via CYP2D6, CYP1A2, and CYP3A4 1

Renal Impairment

Dose reduction is necessary based on severity of renal dysfunction:

• Moderate renal impairment (GFR 11-39 mL/min/1.73 m²): Clearance reduced by 30% 1
• Severe renal impairment (GFR <10 mL/min/1.73 m²): Clearance reduced by 50% 1
• Practical dosing: Start at 7.5-15 mg in moderate impairment; consider 7.5 mg or every-other-day dosing in severe impairment

Drug Interaction Adjustments

CYP3A4 Strong Inducers (Carbamazepine, Phenytoin, Rifampin)

Mirtazapine dose may need to be doubled when combined with strong CYP3A4 inducers. 1

• Carbamazepine increases clearance 2-fold, decreasing mirtazapine concentrations by 60% 1
• Phenytoin similarly increases clearance 2-fold, decreasing concentrations by 45% 1
• Increase mirtazapine dose by 50-100% when starting these agents; conversely, reduce dose when discontinuing the inducer 1

CYP3A4 Strong Inhibitors (Ketoconazole, Clarithromycin)

Reduce mirtazapine dose by approximately 30-40% when combining with strong CYP3A4 inhibitors. 1

• Ketoconazole increases peak levels by 40% and AUC by 50% 1
• Start at 7.5-10 mg if initiating mirtazapine with a strong inhibitor already on board

Cimetidine

Reduce mirtazapine dose by 30-40% when cimetidine is co-administered. 1

• Cimetidine increases mirtazapine AUC by more than 50% 1

Paroxetine and Fluvoxamine

Recent 2026 population pharmacokinetic data identifies these SSRIs as requiring dose adjustments:

• Paroxetine: Reduces clearance by 26.9% - consider reducing mirtazapine to 22.5-30 mg daily 4
• Fluvoxamine: Reduces clearance by 51.1% - reduce mirtazapine to 15 mg daily 4

Body Mass Index Considerations

Obese patients (BMI ≥28 kg/m²) demonstrate 29.4% reduced clearance and require dose reduction. 4

• Recommended dose for obese patients: 22.5-30 mg daily rather than standard 30-37.5 mg
• This is a newly recognized factor from 2026 population pharmacokinetic modeling

Critical Monitoring Points

Discontinuation

Taper mirtazapine gradually rather than stopping abruptly to minimize withdrawal symptoms. 1 While specific tapering schedules aren't provided in the FDA label, the 20-40 hour half-life suggests reducing by 7.5-15 mg every 1-2 weeks.

MAOI Interactions

Maintain a 14-day washout period both before starting mirtazapine after an MAOI and before starting an MAOI after mirtazapine. 1

Hepatic Monitoring

Monitor liver enzymes periodically, particularly in the first months of therapy. Even low-dose mirtazapine (used for insomnia) has been associated with asymptomatic hepatotoxicity that resolved upon discontinuation 5.

Common Pitfalls

• Sedation paradox: Sedation is actually more prominent at subtherapeutic doses (7.5 mg) due to predominant H1 antagonism; this decreases at therapeutic doses (≥15 mg) as noradrenergic effects emerge 6
• Premature dose escalation: Waiting less than 1 week between increases doesn't allow adequate time to assess response given the 5-day time to steady state 1
• Ignoring sex differences: Women have 18% higher concentration-to-dose ratios and longer elimination half-lives, potentially requiring lower maintenance doses 7
• Overlooking metabolic effects: Weight gain and increased appetite occur in 10-11% of patients and may be particularly problematic in patients with hepatic steatosis or metabolic syndrome 3, 8